

To Whom It May Concern

KYORIN Co., Ltd.

Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen  
for THE LANCET Paper of the Year 2008

Tokyo-January 29, 2009, KYORIN Co., Ltd. announces that a research paper<sup>※1</sup> on a clinical trial (PEACE Study<sup>※2</sup>) of MUCODYNE®, sold by its wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Itaru Kojo), has been selected Paper of the Year by THE LANCET.

Implemented from April 2005 to October 2006 in Japan and China, the PEACE study is a clinical trial to verify the controlling effect of MUCODYNE® on acute exacerbation in COPD patients. As a result, it was verified that MUCODYNE® has an inhibitory effect on acute exacerbation of COPD. Improvements in patient QOL were also observed. Professor Jin-Ping Zheng et al. wrote a paper on the results in China that was featured in the June 2008 issue of the internationally prestigious UK medical journal THE LANCET for its high clinical value.

With the selection criterion being content that had had an impact on actual clinical practice, members of the editorial board of THE LANCET first nominated six papers for the Paper of the Year 2008 among all papers published in 2008. Then, online voting by the editorial board and readers was held between December 19<sup>th</sup> 2008 and January 12<sup>th</sup> 2009. As a consequence (with 21,556 votes cast), the PEACE Study paper was chosen for the top three papers and voted best paper by the readers of THE LANCET.

The reasons for selecting the PEACE Study are outlined below:

- ① The trial was designed to bring benefits and change to current medical treatment and will become a benchmark for future research.
- ② With respect to clinicians and decisions on courses of treatment, the trial is well judged and persuasive of the value of treatment intervention.
- ③ The trial contributes a new treatment strategy for tackling the critical issues posed by the disease and is concerned with public health and worldwide health issues.
- ④ The research raises issues with preventive medical care and, in addition, it contributes new therapeutic measures for treating a disease that has been considered difficult to treat in until now.

KYORIN Pharmaceutical Co., Ltd. will contribute further to the treatment of respiratory ailments by providing the latest information about MUCODYNE®.

※1 : Zheng JP, Kang J, Huang SG, et al, Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study) : a randomised placebo-controlled study. *Lancet* 2008; 371: 2013-18.

※2 : Preventive Effect on Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) with Carbocisteine 1500mg/day

For Further information, Contact:  
KYORIN Co., Ltd.  
Management Planning Department  
Telephone: +81-3-3293-3414  
Fax: +81-3-3293-3454